Hikma Pharmaceuticals Public annual asset turnover
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Asset Turnover Growth & History (HIK)
Hikma Pharmaceuticals Public's asset turnover was 0.62 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.62 | −0.02 | −2.72% |
| 2024 | 2024-12-31 | 0.64 | 0.01 | +1.43% |
| 2023 | 2023-12-31 | 0.63 | 0.06 | +10.38% |
| 2022 | 2022-12-31 | 0.57 | −0.03 | −5.16% |
| 2021 | 2021-12-31 | 0.60 | — | — |
Hikma Pharmaceuticals Public asset turnover trends
Between the periods ended 2021-12-31 and 2025-12-31, Hikma Pharmaceuticals Public's asset turnover increased from 0.60 to 0.62, a change of 0.02.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...